TP53 and neoplasm: Collectively, these structures demonstrate that there are multiple distinct solutions to recognizing the p53R175H neoepitope with sufficient on-target affinity and specificity to mediate the killing of tumor cells expressing mutant p53 without affecting normal cells expressing WT p53, a critical consideration for avoiding adverse clinical events in ACT due to off-target TCR recognition (20).